Low ratio of n3:n6 fatty acids correlates with CAD progression

Low ratio of n3:n6 fatty acids correlates with CAD progression
For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

(HealthDay)—For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

Tsuyoshi Nozue, M.D., of the Yokohama Sakae Kyosai Hospital in Japan, and colleagues evaluated the effects of serum n-3 to n-6 PUFA ratios on in 101 statin-treated patients with coronary artery disease who were evaluated using virtual histology ultrasound. The patients were assessed at the time of percutaneous coronary intervention and after eight months of statin therapy.

At follow-up, the researchers found that 46 percent of patients showed atheroma progression and 54 percent exhibited atheroma regression. There were significant negative correlations seen for the change in plaque volume and in the change in fibrous component volume with the changes in the ratios of eicosapentaenoic acid (EPA)/arachidonic acid (AA), docosahexaenoic acid (DHA)/AA, and EPA+DHA/AA. The change in EPA+DPA/AA ratio was a significant predictor of the percentage change in both plaque volume and fibrous component volume in multivariate analysis.

"In conclusion, decreases in serum n-3 to n-6 polyunsaturated fatty acid ratios are associated with progression in coronary atherosclerosis evaluated using virtual histology intravascular ultrasound in statin-treated patients with ," the authors write.

More information: Abstract
Full Text

Related Stories

Drug may reduce coronary artery plaque

date Oct 12, 2008

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat ...

Recommended for you

PCI beats medical tx in stable ischemic heart disease

date 1 hour ago

(HealthDay)—For patients with stable ischemic heart disease (SIHD) and objective evidence of ischemia, percutaneous coronary intervention (PCI) is associated with lower mortality than medical therapy (MT), ...

One in five people will develop heart failure

date May 05, 2015

One person in five is expected to develop heart failure in developed countries, a disease with no cure but which is largely preventable.It feels as if every breath in and out is through a narrow straw.The ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.